Phar & Vide Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Phar & Vide Pharmaceutical Export Portfolio Dataset — 5 Products, $1.0M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Phar & Vide — Pharmaceutical Exporter Profile (2026) | 5 Products, $1.0M Trade | TransData Nexus

Phar & Vide

Indian Pharmaceutical Exporter · Tuberculosis Medications Specialist · $1.0M Total Trade · DGFT Verified

Phar & Vide is an Indian pharmaceutical exporter with a total trade value of $1.0M across 5 products in 3 therapeutic categories. Based on 32 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Serum ($250.0K), Isoniazid ($236.0K), Rifampicin ($236.0K).

Phar & Vide — Export Portfolio & Destination Treemap

Phar & Vide pharmaceutical export portfolio — 5 products across 3 therapeutic categories. Source: Indian Customs (DGFT).

Who is Phar & Vide? — Company Overview & Market Position

Phar & Vide Life Sciences Private Limited is an Indian pharmaceutical exporter headquartered in Chennai, Tamil Nadu. Established on May 1, 2025, the company is registered under the Corporate Identification Number (CIN) U46497TN2025PTC180063. The authorized capital stands at ₹1.5 million, with a paid-up capital of ₹0.3 million. The registered office is located at No 151,152/203, Agurchand Mansion, Mount Road, Chennai, Tamil Nadu 600002.

The company's ownership structure comprises directors Prakash Chordia and Hastimal Chordia, both appointed on May 1, 2025. Phar & Vide Life Sciences Private Limited is an unlisted private limited company, indicating it is not publicly traded.

In the fiscal year 2022-2026, Phar & Vide reported a total export value of $1.0 million USD, with 32 shipments across five products in three therapeutic categories. The top five exported products include Serum, Isoniazid, Rifampicin, Ethambutol, and Pyrazinamide, collectively accounting for 100% of the company's export portfolio.

What Does Phar & Vide Export? — Product Portfolio Analysis

Top Products by Export Value

1Serum$250.0K

Product Portfolio — Top 5 by Export Value

Phar & Vide exports 5 pharmaceutical products across 3 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Serum	Other	$250.0K	5	0.9%	10
2	Isoniazid	Tuberculosis Medications	$236.0K	8	0.0%	14
3	Rifampicin	Advanced Antibiotics	$236.0K	8	0.0%	15
4	Ethambutol	Tuberculosis Medications	$147.9K	7	0.0%	13
5	Pyrazinamide	Tuberculosis Medications	$138.0K	4	0.0%	13

Phar & Vide exports 5 pharmaceutical products across 3 therapeutic categories with a total export value of $1.0M. The top category is Tuberculosis Medications (51.8% of portfolio), followed by Other (24.8%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Phar & Vide — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Specific details regarding Phar & Vide's manufacturing facilities, including locations, capacities, and specializations, are not publicly disclosed. The company's registered office is situated in Chennai, Tamil Nadu, but there is no publicly available information confirming the presence of manufacturing plants at this location. Given the company's focus on exporting finished pharmaceutical formulations, it is likely that manufacturing operations are conducted at facilities compliant with Good Manufacturing Practices (GMP) standards, though exact details remain undisclosed.

3Key Leadership

Phar & Vide Life Sciences Private Limited is led by directors Prakash Chordia and Hastimal Chordia, both appointed on May 1, 2025. As the company is unlisted and relatively new, detailed profiles of these individuals, including their professional backgrounds and roles within the organization, are not publicly available. The absence of publicly accessible information suggests that the company may be in the early stages of its operations, with leadership roles and responsibilities still being established.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Phar & Vide Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Phar & Vide Life Sciences Private Limited's export activities, as reported in the fiscal year 2022-2026, include a total export value of $1.0 million USD across 32 shipments. The company's product portfolio comprises five finished pharmaceutical formulations in three therapeutic categories. However, specific details regarding the regulatory approvals, market access status, and presence in regulated markets such as the United States, European Union, United Kingdom, Australia, and Japan are not publicly disclosed. The absence of this information indicates that Phar & Vide may not yet have established a significant presence in these markets or that such details have not been made publicly available.

2Emerging Markets

Phar & Vide Life Sciences Private Limited's export activities, as reported in the fiscal year 2022-2026, include a total export value of $1.0 million USD across 32 shipments. The company's product portfolio comprises five finished pharmaceutical formulations in three therapeutic categories. However, specific details regarding the company's penetration into emerging markets such as Africa, Latin America, and Southeast Asia, as well as the status of WHO prequalification enabling access to these regions, are not publicly disclosed. The absence of this information suggests that Phar & Vide may not yet have established a significant presence in these markets or that such details have not been made publicly available.

Phar & Vide — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Phar & Vide Life Sciences Private Limited's interactions with the U.S. Food and Drug Administration (FDA), including facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history, are not publicly disclosed. The absence of this information suggests that the company may not yet have established a significant presence in the U.S. market or that such details have not been made publicly available. Given the company's focus on exporting finished pharmaceutical formulations, it is likely that any interactions with the FDA would pertain to compliance with U.S. regulatory standards for imported pharmaceutical products.

2WHO & EU GMP

Specific details regarding Phar & Vide Life Sciences Private Limited's compliance with World Health Organization (WHO) prequalification, European Union Good Manufacturing Practice (EU GMP) certificates, and European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly disclosed. The absence of this information suggests that the company may not yet have obtained these certifications or that such details have not been made publicly available. Given the company's focus on exporting finished pharmaceutical formulations, obtaining WHO prequalification and EU GMP certification would be essential for accessing international markets and ensuring product quality and safety.

Phar & Vide — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Phar & Vide Life Sciences Private Limited operates in the competitive pharmaceutical export market, focusing on finished pharmaceutical formulations. While specific competitors in overlapping categories are not publicly disclosed, the Indian pharmaceutical export sector is characterized by numerous established companies with diverse product portfolios and global market reach. The company's portfolio concentration, with its top five products accounting for 100% of its export value, may limit its ability to compete effectively against larger, more diversified competitors. To enhance its competitive position, Phar & Vide may consider expanding its product range and exploring new markets.

2Key Differentiators

Phar & Vide Life Sciences Private Limited's key differentiator lies in its focus on exporting finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. This specialization allows the company to cater to the growing global demand for ready-to-use pharmaceutical products. However, the company's portfolio concentration, with its top five products accounting for 100% of its export value, may limit its ability to diversify and mitigate risks associated with market fluctuations. Expanding its product portfolio and obtaining international certifications could further strengthen its competitive advantage.

Strategic Position

Buyer Due Diligence Brief — Evaluating Phar & Vide as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Phar & Vide Life Sciences Private Limited's export activities, as reported in the fiscal year 2022-2026, include a total export value of $1.0 million USD across 32 shipments. The company's product portfolio comprises five finished pharmaceutical formulations in three therapeutic categories. However, specific details regarding the company's track record, export volume consistency, and reliability indicators are not publicly disclosed. The absence of this information suggests that the company may be in the early stages of its operations, with limited public exposure. Prospective partners and clients may consider conducting direct due diligence to assess the company's reliability and performance.

2Certifications to Verify

Prospective importers should verify the following certifications to ensure compliance with international standards:

FDA Registration: Confirm that the company's manufacturing facilities are registered with the U.S. Food and Drug Administration (FDA). This can be verified through the FDA's official website or by contacting the company directly.

Frequently Asked Questions — Phar & Vide

How many pharmaceutical products does Phar & Vide export from India?

Phar & Vide exports 5 pharmaceutical products across 3 therapeutic categories. The top exports are Serum ($250.0K), Isoniazid ($236.0K), Rifampicin ($236.0K), Ethambutol ($147.9K), Pyrazinamide ($138.0K). Total export value is $1.0M.

What is Phar & Vide's total pharmaceutical export value?

Phar & Vide's total pharmaceutical export value is $1.0M, based on 32 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Phar & Vide cover?

Phar & Vide exports across 3 therapeutic categories. The largest are Tuberculosis Medications (51.8%, 3 products), Other (24.8%, 1 products), Advanced Antibiotics (23.4%, 1 products).

Get Full Phar & Vide Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.